CBC Group's portfolio firm Hasten Biopharmaceutical acquires 14 branded products' assets from South Korea's Celltrion.
CBC Group, Asia's largest healthcare asset manager, announces portfolio firm Hasten Biopharmaceutical's acquisition of 14 branded products' asset rights from South Korean biopharma firm Celltrion. This deal, including MAH rights in eight countries, expands Hasten's product pipeline, supply chain, and business reach across Pan-Asia under CBC Group's "investor-operator" approach.
July 01, 2024
3 Articles